Guardant Health, Inc. (GH)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$161.41+0.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Guardant Health aims for 32% to 34% revenue growth in 2026. It plans to keep gross margin near 64% to 65%. Free cash flow burn should shrink to $185-$195 million in 2026. FDA approval and new products support growth.
The company still loses money and free cash flow is negative. Revenue growth could slow below 30%. Profit margins may fall below 64%. Leadership changes could hurt execution.
The price is about 23% above our fair value near $132. Analysts expect 36% revenue growth. Our fair value is below the Street median of $160.
Breaks if: FCF burn exceeds $200 million in FY26
Guardant Health aims to reduce its free cash flow burn to between $185 million and $195 million in 2025.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. GH is currently in a watch state, with recent earnings performance falling short of its peers, which adds uncertainty to its growth trajectory.
The market appears to have priced in a justified valuation, reflecting low fragility and a premium compared to peers. However, there is an expectations gap indicating that investors may be cautious about future performance.
Management has set ambitious revenue growth targets for 2026, and while they are on track, recent financial performance has been weak. The company is also working to reduce free cash flow burn, but progress has been mixed.
The long-term thesis hinges on GH's ability to maintain revenue growth and manage cash flow effectively. Additionally, external factors such as sector performance and macroeconomic conditions will play a significant role in shaping the company's outlook.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat strengthens the read on GH. However, a $245 million patent judgment threatens its financial stability and growth objectives.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: gross margin falls below 62% in FY26
Sustain non-GAAP gross margin within the targeted 64% to 65% range throughout 2026.
Stated as a priority in 3 of last 3 quarters. Non-GAAP gross margin was 66% in 2026-Q1 and 67% in 2026-Q2, consistent with the 64%-65% full year guidance. The margin trajectory is stable and slightly above target, indicating delivery.
“Non-GAAP gross margin was 67% for the second quarter of 2026”
“Non-GAAP gross margin was 66% for the first quarter of 2026”
“Guardant Health expects full year 2026 non-GAAP gross margin to be in the range of 64% to 65%”
Breaks if: YoY revenue growth falls below 30% in FY26
Drive strong revenue growth in 2026, led by Oncology, Screening, and Biopharma & Data segments.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $203.5 million in 2025-Q1 to $335.0 million in 2026-Q2 (44% growth). Full year 2026 revenue guidance was raised from $1.30-$1.32 billion (32%-34% growth) in 2026-Q1 to $1.34-$1.36 billion (36%-38% growth) in 2026-Q2. The trajectory is delivering and accelerating.
“Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%”
“Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34%”
“Expects full year 2026 total revenue to grow in the range of 27% to 30% year-over-year”
In the next 1 to 3 years, GH's performance will depend on its execution against growth targets and the broader healthcare sector's momentum. Not investment advice.